AstraZeneca stock gains analyst support as RBC sets 14,500p target

Published on 09/09/2026 at 15:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock is backed by a new Outperform rating from RBC Capital Markets with a 14,500 pence price target as of September 9, 2026. The shares trade below that level, while recent FDA approval adds a pipeline catalyst for investors.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) was trading near 119.00 pence in London on September 9, 2026, after modest intraday gains left the share price below a fresh analyst target of 14,500 pence set by RBC Capital Markets.

RBC sees compelling risk-reward

According to Investing.com on September 9, 2026, RBC Capital Markets initiated coverage of AstraZeneca at Outperform and set a price target of 14,500 pence, describing the shares as the most compelling risk-reward in its European pharma coverage.

The same note highlights that AstraZeneca’s price-to-earnings multiple has fallen to about 14 times, a 10-year low, after recent clinical setbacks and uncertainty over late-stage data due in the second half of 2026, which RBC says has overly punished the stock.Investing.com

Stock trades below new target

In London trading on September 9, 2026, AstraZeneca shares recently gained about 0.1 percent to 118.92 pence, having opened at 118.50 pence and touched an intraday high of 119.96 pence.finanzen.ch Measured against RBC’s 14,500 pence target, the latest London quote implies upside of roughly 21.8 percent if the shares were to reach that level.

An overview of European markets on September 9, 2026 noted that the FTSE 100 index edged lower, with AstraZeneca among the notable decliners earlier in the session despite the supportive analyst commentary.Saxo Bank

Pipeline boosted by FDA approval

As Benzinga reported on September 8, 2026, AstraZeneca recently secured approval from the U.S. Food and Drug Administration for a new breast cancer treatment, providing a fresh late-stage pipeline catalyst alongside ongoing trials such as SERENA-4 and AVANZAR referenced in RBC’s analysis.

In U.S. trading on September 8, 2026, AstraZeneca’s American depositary shares fell 0.74 percent to USD 161.49 following news of the approval, indicating that investors have yet to fully price in the long-term revenue potential of the new therapy.Benzinga

Additional analyst views and valuation context

RBC’s call adds to existing positive coverage on AstraZeneca’s U.S.-listed shares, where RBC Capital also initiated the ADR at buy with a target price of USD 196.42 on September 9, 2026, reinforcing the firm’s view that the stock offers attractive upside from current levels.Futunn

Alongside RBC, BofA Securities maintains a buy rating on AstraZeneca’s ADR with a target price of USD 223.52 as of September 9, 2026, suggesting further upside beyond RBC’s U.S. target if the company executes on its growth and pipeline plans.Futunn

One valuation-focused overview on September 8, 2026 estimated AstraZeneca’s fair value at USD 180.91 per share versus a contemporaneous market price of USD 162.70, implying that the stock was about 10.1 percent undervalued on that framework and offering an additional lens on the company’s income potential for long-term investors.GuruFocus

Stock holds modest gains in London

As of the London session on September 9, 2026, AstraZeneca stock remained near 118.92 pence on the London Stock Exchange after a day’s range between 118.50 and 119.96 pence, leaving the shares below both the newly announced 14,500 pence target from RBC and the valuation estimate in U.S. dollar terms mentioned by other analysts.